Fjarde AP Fonden Fourth Swedish National Pension Fund Reduces Stock Position in Illumina, Inc. (NASDAQ:ILMN)

Fjarde AP Fonden Fourth Swedish National Pension Fund lessened its stake in Illumina, Inc. (NASDAQ:ILMN) by 13.4% during the fourth quarter, HoldingsChannel.com reports. The firm owned 34,886 shares of the life sciences company’s stock after selling 5,400 shares during the period. Fjarde AP Fonden Fourth Swedish National Pension Fund’s holdings in Illumina were worth $4,662,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Empowered Funds LLC grew its position in shares of Illumina by 1.7% in the 3rd quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock worth $516,000 after acquiring an additional 66 shares in the last quarter. Bank of Stockton lifted its stake in Illumina by 3.8% during the fourth quarter. Bank of Stockton now owns 2,162 shares of the life sciences company’s stock worth $289,000 after purchasing an additional 80 shares during the last quarter. Caprock Group LLC boosted its holdings in Illumina by 3.0% in the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after purchasing an additional 83 shares during the period. Integrated Advisors Network LLC raised its holdings in shares of Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after purchasing an additional 90 shares during the period. Finally, Stephens Inc. AR lifted its position in shares of Illumina by 1.4% in the 4th quarter. Stephens Inc. AR now owns 6,623 shares of the life sciences company’s stock worth $885,000 after buying an additional 90 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Trading Up 1.9 %

Illumina stock opened at $95.73 on Wednesday. Illumina, Inc. has a 12-month low of $91.92 and a 12-month high of $156.66. The stock has a market capitalization of $15.16 billion, a PE ratio of -12.46, a price-to-earnings-growth ratio of 1.60 and a beta of 1.10. The firm has a 50 day simple moving average of $126.02 and a 200-day simple moving average of $133.80. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on ILMN shares. Piper Sandler boosted their price objective on shares of Illumina from $185.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, February 10th. Guggenheim lowered their target price on Illumina from $170.00 to $150.00 and set a “buy” rating for the company in a report on Friday, February 7th. Citigroup downgraded Illumina from a “buy” rating to a “neutral” rating and cut their price target for the stock from $190.00 to $165.00 in a report on Wednesday, December 11th. Stephens upped their price objective on Illumina from $170.00 to $184.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 12th. Finally, Canaccord Genuity Group cut their target price on Illumina from $145.00 to $135.00 and set a “hold” rating on the stock in a research note on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Illumina has an average rating of “Moderate Buy” and an average target price of $159.45.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.